Most Read Articles
Rachel Soon, 26 Jun 2018

MIMS Pharmacist presents an overview of phosphatidylcholine's physiological role, as well as contemporary research on its pharmacology and effects.

17 Mar 2018
Nonvitamin K antagonist oral anticoagulants (NOAC)-associated intracerebral haemorrhage (ICH) and vitamin K antagonists-ICH appear to have similar ICH volume, haematoma expansion, functional outcome and mortality, results of a recent meta-analysis have shown.
31 May 2017
New drug applications approved by US FDA as of 16 - 31 May 2017 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
09 Dec 2017
Intravenous (IV) iron is less toxic and more effective compared to oral iron, making it a potential frontline therapy for neonatal iron deficiency anaemia, suggests a recent study.

Dual inhibition of EGFR, HER3 confers no survival benefit in metastatic colorectal cancer

10 Jun 2018

The dual-action antibody directed against epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 3 (HER3), duligotuzumab, does not appear to provide survival advantage compared with cetuximab in patients with RAS exon 2/3 wild-type metastatic colorectal cancer (mCRC) treated with the FOLFIRI (folinic acid, fluorouracil and irinotecan) regimen, according to the results of a phase II trial.

A total of 134 mCRC patients (median age 62 years; 61 percent male) with KRAS exon 2 wild-type were randomized to receive either duligotuzumab (n=68) or cetuximab (n=66) with FOLFIRI until progression or intolerable toxicity. Researchers performed mutation and biomarker analysis on mandatory tumour samples, as well as efficacy analysis in patients with RAS exon 2/3 wild-type tumours.

Of the patients, 98 had RAS exon 2/3 wild-type tumour, with 53 in the duligotuzumab arm and 45 in the cetuximab arm.

Efficacy data revealed that in the subgroup of patients with RAS wild-type tumours, duligotuzumab did not improve progression-free survival (median PFS, 7.3 vs 5.7 months; stratified hazard ratio [HR], 1.21; 90 percent CI, 0.81–1.81) or overall survival (median OS, 14.0 vs 13.1 months; stratified HR, 1.00; 0.61–1.66) compared with cetuximab. Moreover, a trend toward a lower objective response rate (ORR) was observed in the duligotuzumab arm (19 percent vs 33 percent; stratified HR, 0.47; 0.21–1.01).

There was no association observed between PFS or ORR and ERBB3, NRG1 or AREG expression. In terms of safety, duligotuzumab was associated with fewer skin rash events but more diarrhoea. Additionally, although the incidence of grade ≥3 adverse events (AEs) was similar between the two treatment arms, the frequency of serious AEs was higher with duligotuzumab.

Further development of duligotuzumab has been discontinued.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Rachel Soon, 26 Jun 2018

MIMS Pharmacist presents an overview of phosphatidylcholine's physiological role, as well as contemporary research on its pharmacology and effects.

17 Mar 2018
Nonvitamin K antagonist oral anticoagulants (NOAC)-associated intracerebral haemorrhage (ICH) and vitamin K antagonists-ICH appear to have similar ICH volume, haematoma expansion, functional outcome and mortality, results of a recent meta-analysis have shown.
31 May 2017
New drug applications approved by US FDA as of 16 - 31 May 2017 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
09 Dec 2017
Intravenous (IV) iron is less toxic and more effective compared to oral iron, making it a potential frontline therapy for neonatal iron deficiency anaemia, suggests a recent study.